Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: A phase II trial.

Qiao Li(Guangzhou University of Chinese Medicine), Zijing Wang(Qingdao University), Maiyue He(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiaxuan Liu
Journal of Clinical Oncology
June 1, 2023
10.1200/jco.2023.41.16_suppl.e13038
Cited by 3

Related Papers

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
|Frontiers in Oncology|2022|119
The Novel Autophagy Inhibitor Alpha-Hederin Promoted Paclitaxel Cytotoxicity by Increasing Reactive Oxygen Species Accumulation in Non-Small Cell Lung Cancer Cells
|International Journal of Molecular Sciences|2018|49
Early Gastric Cancer: Current Advances of Endoscopic Diagnosis and Treatment
|Gastroenterology Research and Practice|2016|42
Safety of intraoperative hypothermia for patients: meta-analyses of randomized controlled trials and observational studies
|BMC Anesthesiology|2020|42
Distribution of metastatic disease in the brain in relation to the hippocampus: a retrospective single-center analysis of 6064 metastases in 632 patients
|Oncotarget|2015|36